Eva Lamm Bergström
AstraZeneca (Sweden)(SE)
Publications by Year
Research Areas
Asthma and respiratory diseases, PI3K/AKT/mTOR signaling in cancer, Chronic Myeloid Leukemia Treatments, Cytokine Signaling Pathways and Interactions, Inhalation and Respiratory Drug Delivery
Most-Cited Works
- → The contribution of VEGF signalling to fostamatinib‐induced blood pressure elevation(2013)53 cited
- → Translational Model to Predict Pulmonary Pharmacokinetics and Efficacy in Man for Inhaled Bronchodilators(2017)38 cited
- → Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma(2021)35 cited
- → Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma(2019)22 cited
- → Prevention of fostamatinib‐induced blood pressure elevation by antihypertensive agents(2015)11 cited
- → The discovery of a selective and potent A2aagonist with extended lung retention(2015)8 cited
- → Same lung deposited dose in dog dosing a fine and coarse aerosol indicates no difference in intranasal filtration(2022)1 cited
- → CCDC 1884583: Experimental Crystal Structure Determination(2019)
- → Direct relationship between inhibition of leukotriene release in lung and free plasma concentration of a LTC4synthase inhibitor in a rat model(2015)
- → Pharmacological properties of novel LTC4 synthase inhibitor(2017)